Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Industry Opposes Full Annual Price Revisions at LDP Hearing
November 15, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- Benralizumab, Olaparib, Keytruda’s Urothelial Carcinoma Use Up for MHLW Panel Review/Report on Nov. 24
November 13, 2017
- Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
- Dispensing of Generics Down Slightly Despite Increase in Generic-Name Prescribing: Chuikyo Survey
November 13, 2017
- Japan, US Agree to Extend Chuikyo’s Industry Hearing Time
November 9, 2017
- 3rd-Party Re-Analysis Now Complete; Chuikyo Discusses Pilot CEA Products Closed Door
November 9, 2017
- Driver Gene-Based Drug Discovery Also Applicable for Early Approval System: MHLW
November 8, 2017
- 3 Japanese Plasma Fraction Product Makers Raise Concerns about Low NHI Prices at MHLW Panel
November 8, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel
November 7, 2017
- 3 Chuikyo Subcommittees to Hold Close-Door Debate on Pilot CEA Products Nov. 8
November 7, 2017
- LDP Group Starts Discussions on Drug Pricing Reform, Hears Opinions from JPMA Chief
November 6, 2017
- PMDA’s Review Division Remains in the Red, with Loss of 2-2.5 Billion Yen Expected for Full Year
November 6, 2017
- PMDA Aims to Speed Up Decision-Making, Streamline Operations
November 6, 2017
- MHLW Wants Chuikyo to Consider Measures to Promote Generic-Name Prescribing
November 6, 2017
- MHLW Advisory Panel Backs Nexium’s Pediatric Dosages, Oral Suspension Form
November 6, 2017
- Hefty Hirudoid Prescriptions Now under Scrutiny, Chuikyo Members at Odds over Restrictions
November 6, 2017
- Heads of Medicines Regulatory Agencies Agree to Promote Global Harmonization to Enable Use of Real World Data as Evidence
November 2, 2017
- Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
- Clinical Research Review System Based on Clinical Research Law to Start at Minimum of 11 Locations: MHLW
November 2, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…